Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$174.72 USD

174.72
8,075,429

+0.30 (0.17%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $175.51 +0.79 (0.45%) 7:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for HDV

Zacks Equity Research

AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter Humira LOE.

Zacks Equity Research

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie

by Zacks Equity Research

J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.

Zacks Equity Research

Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VTV

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.

Zacks Equity Research

The Zacks Analyst Blog Highlights Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina

by Zacks Equity Research

Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina have been included in this Analyst Blog.

Zacks Equity Research

Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHV

Neena Mishra headshot

ETF Mid-Year Outlook & Investing Strategies

by Neena Mishra

We discuss the market outlook and investing strategies for the rest of 2022.

Sheraz Mian headshot

Top Analyst Reports for Johnson & Johnson, Cigna, & Vertex

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Cigna Corporation (CI), and Vertex Pharmaceuticals Incorporated (VRTX).

Zacks Equity Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Sweta Killa headshot

JNJ Beats on Q2 Earnings, Cuts View: ETFs in Focus

by Sweta Killa

Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.

Zacks Equity Research

Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for LVHD

Zacks Equity Research

U.S. Housing Starts Declined in June

by Zacks Equity Research

U.S. Housing Starts Declined in June

Mark Vickery headshot

Pre-Markets Try Again for Gains; J&J, Halliburton Beat in Q2

by Mark Vickery

This morning, we're seeing modestly higher levels that have not changed much since economic and Q2 earnings data has dropped.

Zacks Equity Research

GSK Completes Demerger of Consumer Healthcare Business

by Zacks Equity Research

Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.

Zacks Equity Research

J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance

by Zacks Equity Research

J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.

Zacks Equity Research

Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.78% and 0.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWV

Sejuti Banerjea headshot

Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood

by Sejuti Banerjea

JNJ Management expects relatively consistent growth for the rest of the year.

Mark Vickery headshot

Apple (AAPL) Spending Cuts Drain Rally; IBM Beats Again

by Mark Vickery

A report regarding Apple Inc. (AAPL) slowing its pace of hiring and spending in some (as yet undetermined) segments sent shares down -2%.

Zacks Equity Research

Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWD

Zacks Equity Research

J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued in the second.

Zacks Equity Research

The Zacks Analyst Blog Highlights Synchrony Financial, Johnson & Johnson, J.B. Hunt Transport Services, Citizens Financial Group, and Truist Financial

by Zacks Equity Research

Synchrony Financial, Johnson & Johnson, J.B. Hunt Transport Services, Citizens Financial Group, and Truist Financial are part of Zacks top Analyst Blog.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Coca-Cola, Kroger and Johnson & Johnson

by Zacks Equity Research

Coca-Cola, Kroger and Johnson & Johnson are part of Zacks Investment Ideas article.